Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Clément, Bolognini"'
Autor:
Elodie Klajer, Marine Jary, Angélique Vienot, Aurélia Meurisse, Francine Fein, Clément Bolognini, Syrine Abdeljaoued, Hortense Chevalier, Dewi Vernerey, Meher Nasri, Anthony Turpin, Stefano Kim, Hamadi Almotlak, Thierry Nguyen, Christophe Borg, Elisabeta Gherga, Fabien Calcagno, Christelle d’Engremont
Publikováno v:
World Journal of Gastrointestinal Oncology. 12:332-346
FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study
Défaut de réparation de l’ADN : nouvelle piste thérapeutique pour le cancer de prostate métastatique
Autor:
Yohann Loriot, Clément Bolognini, Elodie Klajer, Guillaume Meynard, Antoine Thiery-Vuillemin, Noémie Gassian
Publikováno v:
Bulletin du Cancer. 105:944-954
Genetic instability is one part of the oncogenic process. Gene mutations involved in DNA repair mechanisms can promote this genetic instability and participate in oncogenesis and metastatic progression. In prostate cancer, DNA repair abnormalities ma
Autor:
Angélique, Vienot, Hortense, Chevalier, Clément, Bolognini, Elisabeta, Gherga, Elodie, Klajer, Aurélia, Meurisse, Marine, Jary, Stefano, Kim, Christelle, d'Engremont, Thierry, Nguyen, Fabien, Calcagno, Hamadi, Almotlak, Francine, Fein, Meher, Nasri, Syrine, Abdeljaoued, Anthony, Turpin, Christophe, Borg, Dewi, Vernerey
Publikováno v:
World Journal of Gastrointestinal Oncology
BACKGROUND FOLFIRINOX regimen is the first-line reference chemotherapy (L1) in advanced pancreatic ductal adenocarcinoma (aPDAC). FOLFOXIRI, a schedule with a lower dose of irinotecan and no bolus 5-fluorouracil, has demonstrated efficacy and feasibi
Autor:
Yohann, Loriot, Guillaume, Meynard, Elodie, Klajer, Clément, Bolognini, Noémie, Gassian, Antoine, Thiery-Vuillemin
Publikováno v:
Bulletin du cancer. 105(10)
Genetic instability is one part of the oncogenic process. Gene mutations involved in DNA repair mechanisms can promote this genetic instability and participate in oncogenesis and metastatic progression. In prostate cancer, DNA repair abnormalities ma